Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹7,030 Cr
P/E Ratio
25.62
P/B Ratio
3.02
Industry P/E
37.26
Debt to Equity
0
ROE
14.96 %
ROCE
19.62 %
Div. Yield
0 %
Book Value
143.04
EPS
16.85
CFO
₹1,713.48 Cr
EBITDA
₹2,597.27 Cr
Net Profit
₹2,104.78 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
FDC
| -14.41 | 3.27 | -10.26 | -4.72 | 14.67 | 13.29 | 10.75 |
|
BSE Healthcare
| -6.36 | 0.41 | -0.66 | 22.87 | 19.05 | 22.87 | 9.80 |
|
BSE Small Cap
| -10.22 | 4.01 | -4.88 | 8.27 | 18.77 | 36.02 | 15.81 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
FDC
| 26.70 | 46.37 | -10.96 | -8.58 | 56.10 | 22.36 | -30.74 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 5,169.00 | 8,573.83 | 36.24 | 43.77 | |
| 681.25 | 6,630.22 | 75.1 | 4.01 | |
| 630.85 | 5,916.85 | 21.95 | 12.68 | |
| 743.35 | 6,055.12 | 34.7 | 20.28 |
1 min read•By Dhruv Singhvi
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological,... vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Ziglim Plus 2, Vitcofol, Pyrimon DF, Zocon, Zoxan, Zathrin, Zipod, Amodep-AT, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Electral, Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. The company was founded in 1936 and is headquartered in Mumbai, India. Read more
Incorporated
1940
Chairman
Uday Kumar Gurkar
Managing Director
Mohan A Chandavarkar
Headquarters
Chhatrapati Sambhajinagar - (Aurangabad), Maharashtra
Website
Looking for more details about FDC Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of FDC Ltd stood at ₹ 2,688 Cr as on 31-Dec-24
The share price of FDC Ltd is ₹427.50 (NSE) and ₹427.80 (BSE) as of 22-Apr-2025 12:19 IST. FDC Ltd has given a return of 14.67% in the last 3 years.
FDC Ltd has a market capitalisation of ₹ 7,030 Cr as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of FDC Ltd is 3.02 times as on 22-Apr-2025, a 42% discount to its peers’ median range of 5.18 times.
The P/E ratio of FDC Ltd is 25.62 times as on 22-Apr-2025, a 31% discount to its peers’ median range of 37.26 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the FDC Ltd and enter the required number of quantities and click on buy to purchase the shares of FDC Ltd.
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Ziglim Plus 2, Vitcofol, Pyrimon DF, Zocon, Zoxan, Zathrin, Zipod, Amodep-AT, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Electral, Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. The company was founded in 1936 and is headquartered in Mumbai, India.
The prominent promoters of FDC Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
NOMITA R CHANDAVARKAR |
22.67%
|
|
NANDAN MOHAN CHANDAVARKAR (in capacity of trustee of Sandhya Mohan Chandavarkar Trust) |
11.01%
|
|
NANDAN MOHAN CHANDAVARKAR(in capacity of trustee of Mohan Anand Chandavarkar Trust |
10.81%
|
|
LEO ADVISORS PVT LTD |
9.17%
|
|
VIRGO ADVISORS PVT LTD |
6.12%
|
The chairman of the company is Uday Kumar Gurkar, and the managing director is Mohan A Chandavarkar.
There is no promoter pledging in FDC Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,680
|
|
|
6,570
|
|
|
6,016
|
|
|
6,001
|
| FDC Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
12.5
|
|
Operating margin(%)
|
13.05
|
|
Net Margin(%)
|
12.58
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of FDC Ltd was ₹274 Cr.
₹-3.10
(
